Raynaud’s Disease- Pipeline Insight, 2024

Raynaud’s Disease- Pipeline Insight, 2024

DelveInsight’s, “Raynaud’s Disease- Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Raynaud’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Raynaud’s Disease: Understanding

Raynaud’s Disease: Overview

Raynaud’s phenomenon is a problem that causes decreased blood flow to the fingers. In some cases, it also causes less blood flow to the ears, toes, nipples, knees, or nose. This happens due to spasms of blood vessels in those areas. The spasms happen in response to cold, stress, or emotional upset. Raynaud’s can occur on its own, known as primary form. Or it may happen along with other diseases, known as secondary form. The exact cause of Raynaud’s is unknown. It is possible that some blood disorders may cause Raynaud’s by increasing the blood thickness. This may happen due to excess platelets or red blood cells. Or special receptors in the blood that control the narrowing of the blood vessels may be more sensitive. Symptoms can occur a bit differently in each person. Common symptoms include: Fingers that turn pale or white then blue when exposed to cold, or during stress or emotional upset, then red when the hands are warmed, hands that may become swollen and painful when warmed, sores on the finger pads develop, in severe cases, gangrene in the fingers that causes infection or needs amputation, this is rare. Raynaud's phenomenon treatment depend on symptoms, age and general health. It also depend on how severe the condition is. There is no cure for Raynaud’s phenomenon, but it can be managed with proper treatment. The complications of Raynaud’s phenomenon is in rare cases, sores on finger pads may occur. These sores may progress to gangrene. In rare cases, gangrene may lead to finger amputation. For most people living with Raynaud’s, it is more of an inconvenience than a serious problem. Avoiding triggers, primarily cold, can reduce the spasms that lead to symptoms. If there is an underlying cause, such as scleroderma or lupus, it may be more difficult to manage attacks. Managing Raynaud’s includes avoiding cold, dressing warmly, and stopping smoking.

“Raynaud’s Disease- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Raynaud’s Disease pipeline landscape is provided which includes the disease overview and Raynaud’s Disease treatment guidelines. The assessment part of the report embraces, in depth Raynaud’s Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Raynaud’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Raynaud’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve Raynaud’s Disease.

Raynaud’s Disease Emerging Drugs Chapters

This segment of the Raynaud’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Raynaud’s Disease Emerging Drugs

• GS 248: Gesynta Pharma

GS-248 is Gesynta Pharma’s most advanced drug candidate, currently in clinical development as a potential treatment of Raynaud’s phenomenon. Gesynta Pharma is currently conducting a placebo-controlled clinical study in order to document the safety and efficacy profile of GS-248 during a four-week-treatment in circa 80 patients. The participants have been diagnosed with systemic sclerosis and exhibit recurrent Raynaud’s phenomenon. The study is primarily tracking patients’ symptoms, including the frequency of Raynaud attacks, but also documenting digital blood flow as well as inflammatory biomarkers. The study, is conducted in four European countries, is coordinated by the University of Manchester Centre for Musculoskeletal Research.

• Treprostinil: United Therapeutics

Treprostinil is an investigational drug being developed by United Therapeutics. Currently, the drug is in Early Phase I for the treatment of Raynaud's phenomenon. Treprostinil, basically acts as a platelet aggregation inhibitor.

Further product details are provided in the report……..

Raynaud’s Disease: Therapeutic Assessment

This segment of the report provides insights about the different Raynaud’s Disease drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Raynaud’s Disease

There are approx. 5+ key companies which are developing the therapies for Raynaud’s Disease. The companies which have their Raynaud’s Disease drug candidates in the most advanced stage, i.e. phase II include, Gesynta Pharma.

• Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Raynaud’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Raynaud’s Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Raynaud’s Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Raynaud’s Disease drugs.

Raynaud’s Disease Report Insights

• Raynaud’s Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Raynaud’s Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Raynaud’s Disease drugs?
• How many Raynaud’s Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Raynaud’s Disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Raynaud’s Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Raynaud’s Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Gesynta Pharma
• United Therapeutics
• Vicore Pharma
• Arena Pharmaceuticals

Key Products

• GS 248
• Treprostinil
• C21
• Temanogrel